Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.-论文-万方医学网

作者： Reinhard,Dummer ^[1] ; Jan C,Brase ^[2] ; James,Garrett ^[3] ; Catarina D,Campbell ^[3] ; Eduard,Gasal ^[4] ; Matthew,Squires ^[2] ; Daniel,Gusenleitner ^[3] ; Mario,Santinami ^[5] ; Victoria,Atkinson ^[6] ; Mario,Mandalà ^[7] ; Vanna,Chiarion-Sileni ^[8] ; Keith,Flaherty ^[9] ; James,Larkin ^[10] ; Caroline,Robert ^[11] ; Richard,Kefford ^[12] ; John M,Kirkwood ^[13] ; Axel,Hauschild ^[14] ; Dirk,Schadendorf ^[15] ; Georgina V,Long ^[16]

作者单位： University Hospital Zürich Skin Cancer Center, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch. ^[1] Novartis Pharma, Basel, Switzerland. ^[2] Novartis Institutes for BioMedical Research, Cambridge, MA, USA. ^[3] Novartis Pharmaceuticals, East Hanover, NJ, USA. ^[4] Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[5] Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane, QLD, Australia. ^[6] Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy. ^[7] Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. ^[8] Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. ^[9] Royal Marsden NHS Foundation Trust, London, UK. ^[10] Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France. ^[11] Macquarie University and Westmead Hospital, Sydney, NSW, Australia; Melanoma Institute Australia and The University of Sydney, Sydney, NSW, Australia. ^[12] Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. ^[13] University Hospital Schleswig-Holstein, Kiel, Germany. ^[14] University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany. ^[15] Melanoma Institute Australia and The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. ^[16]

主题词青少年(Adolescent);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);双盲法(Double-Blind Method);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);咪唑类(Imidazoles);男(雄)性(Male);黑色素瘤(Melanoma);中年人(Middle Aged);突变(Mutation);肿瘤转移(Neoplasm Metastasis);肿瘤复发, 局部(Neoplasm Recurrence, Local);肟类(Oximes);预后(Prognosis);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);吡啶酮类(Pyridones);嘧啶酮类(Pyrimidinones);挽救疗法(Salvage Therapy);皮肤肿瘤(Skin Neoplasms);存活率(Survival Rate);青年人(Young Adult)

DOI 10.1016/S1470-2045(20)30062-0

PMID 32007138

发布时间 2020-07-06

检索历史清除

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.

The Lancet. Oncology

相似文献

The Lancet. Oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.

The Lancet. Oncology

相似文献

The Lancet. Oncology

相关期刊

检索历史清除